Your browser doesn't support javascript.
loading
Unraveling SSc Pathophysiology; The Myofibroblast.
van Caam, Arjan; Vonk, Madelon; van den Hoogen, Frank; van Lent, Peter; van der Kraan, Peter.
Affiliation
  • van Caam A; Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands.
  • Vonk M; Department of Rheumatology, Radboudumc, Nijmegen, Netherlands.
  • van den Hoogen F; Department of Rheumatology, Radboudumc, Nijmegen, Netherlands.
  • van Lent P; Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands.
  • van der Kraan P; Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands.
Front Immunol ; 9: 2452, 2018.
Article in En | MEDLINE | ID: mdl-30483246
ABSTRACT
Systemic sclerosis (SSc) is a severe auto-immune disease, characterized by vasculopathy and fibrosis of connective tissues. SSc has a high morbidity and mortality and unfortunately no disease modifying therapy is currently available. A key cell in the pathophysiology of SSc is the myofibroblast. Myofibroblasts are fibroblasts with contractile properties that produce a large amount of pro-fibrotic extracellular matrix molecules such as collagen type I. In this narrative review we will discuss the presence, formation, and role of myofibroblasts in SSc, and how these processes are stimulated and mediated by cells of the (innate) immune system such as mast cells and T helper 2 lymphocytes. Furthermore, current novel therapeutic approaches to target myofibroblasts will be highlighted for future perspective.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Myofibroblasts Limits: Humans Language: En Journal: Front Immunol Year: 2018 Document type: Article Affiliation country: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Myofibroblasts Limits: Humans Language: En Journal: Front Immunol Year: 2018 Document type: Article Affiliation country: Países Bajos